The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for ...

Many cancers can be treated by administering DNA-damaging agents, such as platinum-based chemotherapy, because the resulting DNA damage causes the cancer cells to die. A subset of cancers, however, ...

Akeso (AKESF) said its experimental lung cancer treatment ivonescimab improved overall survival compared with a widely used ...

PD-1 inhibitors versus PD-L1 inhibitors in PD-L1–negative advanced non-small cell lung cancer: A meta-analysis of survival outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting ...

Researchers at Duke-NUS Medical School have identified a molecular switch controlled by the protein GATA6 that determines whether pancreatic cancer cells respond to chemotherapy or become resistant.

The AIM-HIGH trial showed significant DFS improvement in high-risk stage 1a to 2a nonsquamous NSCLC patients receiving adjuvant chemotherapy. At 24 months, 96% of chemotherapy patients were alive ...

Scientists have identified a crucial molecular switch that decides whether pancreatic cancer cells resist chemotherapy or respond to it. The key player, a gene called GATA6, keeps tumours in a more ...

Metronomic chemotherapy with capecitabine (Xeloda) plus an aromatase inhibitor (AI) could be a first-line treatment option for some patients with HR-positive, HER2-negative metastatic breast cancer, ...

Triple-negative breast cancer (TNBC) was first described as a distinct disease entity 20 years ago. Since that time, there has been tremendous effort invested in understanding the clinical features ...